The recommendation was based on results from the Phase III THOR trial, which compared Balversa to chemotherapy.

Hundreds will benefit after the first targeted treatment for the most common form of bladder cancer was given the green light ...

Hundreds of patients are expected to benefit from the recommendation by the National Institute of Health and Care Excellence.

Bavencio as first-line maintenance was associated with long-term efficacy in advanced urothelial carcinoma regardless of ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable NSCLC ...

AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

The European Commission on Friday approved AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo's (OTC:DSKNY) Enhertu (trastuzumab ...

Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...